Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2006 1
2007 6
2008 3
2010 6
2011 10
2012 3
2013 2
2014 4
2015 1
2016 4
2017 3
2018 4
2019 6
2020 9
2021 7
2022 13
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor.
Koblish HK, Wu L, Wang LS, Liu PCC, Wynn R, Rios-Doria J, Spitz S, Liu H, Volgina A, Zolotarjova N, Kapilashrami K, Behshad E, Covington M, Yang YO, Li J, Diamond S, Soloviev M, O'Hayer K, Rubin S, Kanellopoulou C, Yang G, Rupar M, DiMatteo D, Lin L, Stevens C, Zhang Y, Thekkat P, Geschwindt R, Marando C, Yeleswaram S, Jackson J, Scherle P, Huber R, Yao W, Hollis G. Koblish HK, et al. Among authors: yeleswaram s. Cancer Discov. 2022 Jun 2;12(6):1482-1499. doi: 10.1158/2159-8290.CD-21-1156. Cancer Discov. 2022. PMID: 35254416 Free PMC article. Clinical Trial.
Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream.
Smith P, Yao W, Shepard S, Covington M, Lee J, Lofland J, Naim A, Sheth T, Parikh B, Yeleswaram S. Smith P, et al. Among authors: yeleswaram s. Pharmaceutics. 2021 Jul 8;13(7):1044. doi: 10.3390/pharmaceutics13071044. Pharmaceutics. 2021. PMID: 34371735 Free PMC article. Review.
Discovery of Pyrazolopyridine Derivatives as HPK1 Inhibitors.
Ye Q, Liu K, Ye HF, Pan J, Sokolsky A, Wang A, Zhang K, Hummel JR, Kong L, Behshad E, He X, Conlen P, Stump K, Ye M, Diamond S, Covington M, Yeleswaram S, Atasoylu O, Vechorkin O, Yao W. Ye Q, et al. Among authors: yeleswaram s. ACS Med Chem Lett. 2022 Dec 12;14(1):5-10. doi: 10.1021/acsmedchemlett.2c00238. eCollection 2023 Jan 12. ACS Med Chem Lett. 2022. PMID: 36655125 Free PMC article.
Discovery of 5,7-Dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-ones as Highly Selective CDK2 Inhibitors.
Sokolsky A, Winterton S, Kennedy K, Drake K, Stump K, Huo L, Lo Y, Ye M, Covington M, Diamond S, Yang YO, Kim S, Yeleswaram S, Wu L, Yao W. Sokolsky A, et al. Among authors: yeleswaram s. ACS Med Chem Lett. 2022 Oct 6;13(11):1797-1804. doi: 10.1021/acsmedchemlett.2c00408. eCollection 2022 Nov 10. ACS Med Chem Lett. 2022. PMID: 36385925 Free PMC article.
Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib.
Barbour AM, Rockich K, Cimino E, Zhou G, Leonetti-Whalen C, Chen X, Yeleswaram S, Epstein N, Punwani N. Barbour AM, et al. Among authors: yeleswaram s. J Clin Pharmacol. 2021 Jul;61(7):954-960. doi: 10.1002/jcph.1814. Epub 2021 Jan 28. J Clin Pharmacol. 2021. PMID: 33434286
Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2.
Nguyen MH, Atasoylu O, Wu L, Kapilashrami K, Pusey M, Gallagher K, Lai CT, Zhao P, Barbosa J, Liu K, He C, Zhang C, Styduhar ED, Witten MR, Chen Y, Lin L, Yang YO, Covington M, Diamond S, Yeleswaram S, Yao W. Nguyen MH, et al. Among authors: yeleswaram s. ACS Med Chem Lett. 2022 Jun 22;13(7):1159-1164. doi: 10.1021/acsmedchemlett.2c00206. eCollection 2022 Jul 14. ACS Med Chem Lett. 2022. PMID: 35859885 Free PMC article.
75 results